INTRODUCTION
============

The microaerophilic gram-negative bacterium, *Helicobacter pylori*, is a spiral organism that is strongly associated with chronic gastritis, gastric ulcers, and gastric cancers \[[@B1]\]. *H. pylori* prevalence is often higher than 50% in southern and eastern Europe, South America and Asia, while about a third of adults are still infected in northern Europe and North America \[[@B2]\]. Proton pump inhibitor-clarithromycin-based triple therapy is the first-line choice for eradicating *H. pylori*, but the eradication rate of this treatment against *H. pylori* has decreased to around 80%, mainly due to antibiotic resistance \[[@B3]\]. Given that the current standard therapies for treating *H. pylori* are insufficient, we need to identify alternative options to prevent and eradicate the diseases associated with this pathogen \[[@B4]\].

There are various *Helicobacter* species including *H. pylori*, *H. felis*, *H. bizzozeronii*, and *H. salomnis* colonizing the stomachs of animals \[[@B5]\]. Although gastritis in human and animal is caused by *Helicobacter*, they usually induce asymptomatic infection in the hosts. But, clinical signs such as chronic vomiting and weight loss in pet animals can occur due to gastritis associated with *Helicobacter* \[[@B6]\]. While treating *Helicobacter* infection in dogs and cats is still controversial, a study suggested cats may be a potential natural reservoir of *H. pylori* and cats with *H. pylori* infection induce more severe gastritis than those with *H. felis* or *H. heilmannii* \[[@B7]\].

*H. pylori* colonization induces an inflammatory reaction in the gastric mucosa; this is mediated by neutrophils and mononuclear cells and is characterized by the up-regulation of various cytokines, including interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor alpha (TNF-α) \[[@B8]\]. In gastric mucosa, inflammatory cytokines have been shown to generate reactive oxygen species (ROS) \[[@B9]\]. During the inflammatory response, ROS impair the important biomolecules, such as DNA, lipids, and proteins leading to gastric mucosal injury, while conversely triggering the production of malondialdehyde (MDA), which is a cytotoxic molecule \[[@B10]\]. This inflammatory reaction is accompanied by the up-regulation of nitric oxide (NO) and prostaglandin E~2~, which are induced by the overexpression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) \[[@B11]\].

The herbal remedy called Cheonwangbosim-dan (CBD) in Korean and Tian Wang Bu Xin Dan in Chinese is one of the most popular traditional herbal formulas in East Asian countries. CBD consists of 15 medicinal herbs: *Rehmannia glutinosa*, *Coptis japonica*, *Acorus gramineus*, *Panax ginseng*, *Angelica gigas*, *Schisandra chinensis*, *Asparagus cochinchinensis*, *Liriope platyphylla*, *Thuja orientalis*, *Ziziphus jujuba*, *Scrophularia buergeriana*, *Poria cocos*, *Salvia miltiorrhiza*, *Platycodon grandiflorum*, and *Polygala tenuifolia* \[[@B12]\]. It has been commonly used to treat arterial or auricular flutter, neurosis, insomnia, and cardiac malfunction-induced disease \[[@B13]\]. CBD has been shown to have a variety of biological activities, including neurological, vasorelaxant, and hypotensive effects \[[@B14]\]. However, the effect of CBD against *H. pylori* has not been examined. In the present work, we therefore examined whether CBD has antimicrobial activity against *H. pylori* in AGS cells and model mice that has been used extensively in *Helicobacter* research \[[@B15]\].

MATERIALS AND METHODS
=====================

Chemicals, materials and CBD preparation
----------------------------------------

Berberine chloride (PubChem CID: 12456, purity 98.0%), cinnamic acid (PubChem CID: 444539, purity 99.5%), and coptisine chloride (PubChem CID: 72321, purity 98.0%) were purchased from Wako Pure Chemical Co. (Japan). (*E*)-harpagoside (PubChem CID: 5281542, purity 98.0%), *β*-asarone (PubChem CID: 5281758, purity 98.1%), nodakenin (PubChem CID: 73191, purity 98.0%), and 5-(hydroxymethyl)-2-furaldehyde (5-HMF; PubChem CID: 237332, purity 99.0%) were purchased from ChemFaces (China), Carl Roth (Germany), NPC Bio Technology (Korea), and Merck KGaA (Germany), respectively. High-performance liquid chromatography (HPLC)-grade acetonitrile and water were purchased from J.T. Baker (USA) and anhydrous acetic acid was purchased from Merck KGaA.

Powdered CBD water extract was prepared by the Korea Institute of Oriental Medicine (Korea). Crude preparations of 15 herbs ([Table 1](#T1){ref-type="table"}) were extracted with a 10-fold mass of distilled water at 100°C for 2 h under pressure (98 kPa) using an electric extractor (COSMOS-660; Kyungseo Machine Co., Korea). The extracted water solution was filtered through a standard sieve (No. 270, 53 μm; Chung Gye Sang Gong Sa, Korea) and freeze-dried using a vacuum control freeze dryer (PVT100; IlShinBioBase, Korea) to yield a powder of water decoction. Preparation of CBD water extract is described in The Korean Herbal Pharmacopoeia with regard to standard manufacturing processes \[[@B16]\]. In addition, we previously reported a study on the simultaneous analysis using HPLC and LC-MS/MS for quality assessment of CBD \[[@B17][@B18]\].

###### Composition of Cheonwangbosim-dan
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  Herbal name                   Scientific name               Origin               Amount (g)
  ----------------------------- ----------------------------- -------------------- ------------
  Rehmanniae Radix              *Rehmannia glutinosa*         Andong, Korea        15.0
  Coptidis Rhizoma              *Coptis japonica*             China                7.5
  Acori Graminei Rhizoma        *Acorus gramineus*            Jeju, Korea          3.75
  Ginseng Radix Alba            *Panax ginseng*               Yeongju, Korea       1.875
  Angelicae Gigantis Radix      *Angelica gigas*              Bonghwa, Korea       1.875
  Schizandrae Fructus           *Schisandra chinensis*        Samcheok, Korea      1.875
  Asparagi Tuber                *Asparagus cochinchinensis*   China                1.875
  Liriope Tuber                 *Liriope platyphylla*         Miryang, Korea       1.875
  Thujae Semen                  *Thuja orientalis*            China                1.875
  Zizyphi Semen                 *Zizyphus jujuba*             China                1.875
  Scrophulariae Radix           *Scrophularia buergeriana*    Uiseong, Korea       1.875
  Poria Sclerotium              *Poria cocos*                 Pyeongchang, Korea   1.875
  Salviae Miltiorrhizae Radix   *Salvia miltiorrhiza*         China                1.875
  Platycodi Radix               *Platycodon grandiflorum*     Muju, Korea          1.875
  Polygalae Radix               *Polygala tenuifolia*         China                1.875
  Total amount                  \-                            \-                   48.75

HPLC analysis of CBD
--------------------

Chromatographic analysis of 5-HMF, coptisine chloride, berberine chloride, nodakenin, (*E*)-harpagoside, cinnamic acid, and *β*-asarone was performed with a Prominence LC-20A series HPLC system (Shimadzu Co., Japan), which consisted of a solvent delivery unit (LC-20AT), online degasser (DGU-20A~3~), column oven (CTO-20A), auto sample injector (SIL-20AC), and photo-diode array (PDA) detector (SPD-M20A). The measured data were processed using LCsolution software (Version 1.24; Shimadzu). The major components of the CBD sample were separated using a Gemini C~18~ column (250 mm × 4.6 mm; 5 μm particle size; Phenomenex, USA) at 40°C. The mobile phases consisted of (A) distilled water and (B) acetonitrile, both containing 1.0% (v/v) acetic acid. The gradient condition was as follows: 5--60% B for 0--30 min, 60--100% B for 30--40 min, 100% B for 40--45 min, and 100--5% B for 45--50 min. The flow rate and injection volume were 1.0 mL/min and 10 μL, respectively.

Bacterial strains and cell culture
----------------------------------

*H. pylori* strains SS1, 26695, PED503G, and PED3582GA were supplied by the *H. pylori* Korean Type Culture Collection (Gyeongsang National University School of Medicine, Korea). Each strain was grown on brucella agar plates (Difco, USA) containing 10% fetal bovine serum (FBS; Gibco, USA), in 10% CO~2~ and 100% humidity at 37°C. Human gastric carcinoma AGS (ATCC CRL 1739; ATCC, USA) cells grown in antibiotic-free RPMI-1640 or DMEM (Gibco) supplemented with 10% FBS. CBD, amoxicillin, or clarithromycin at a variety of concentrations were incubated with *H. pylori* suspensions at OD~600~ 1.0 (1 × 10^8^ colony-forming unit \[CFU\]/mL) for 24 h, 100 μL of each bacterial suspension was added to AGS cells, and incubation was continued for 6 h. Supernatants were assessed for the IL-8 level, and proteins were collected from AGS cells.

Disk agar diffusion method
--------------------------

The antimicrobial ability of CBD was tested by the disk agar diffusion method. The CBD extract was dissolved in phosphate buffered saline (PBS) and impregnate 6-mm blank paper disks. As positive controls, we used 2 μg of amoxicillin or clarithromycin (Oxoid, UK). The disks were placed on plates that had been spread with brucella agar (Difco) containing 10% FBS and top coated with 0.1 mL of *H. pylori* suspension at OD~600~ 6.0. The plates were incubated in 10% CO~2~ at 37°C and 100% humidity for 48 h. The diameter of the inhibition zone was recorded for each *H. pylori* strain.

Determination of the minimum inhibitory concentration (MIC)
-----------------------------------------------------------

The broth-dilution method was used to measure the MIC. *H. pylori* were suspended at OD~600~ 1.0 in 10% FBS supplemented-brucella broth and incubated with CBD, amoxicillin, or clarithromycin at a variety of concentrations at 37°C. After 48 h, 100 μL of bacterial suspension was mixed with 100 μL urease reagent (3 mM PBS, pH 5.8, 2% urea, and 7 μg/mL phenol red, pH 5.0). The resulting mixture was incubated for 4 h at 37°C, and a plate reader (Infinite M200 Pro; TECAN, Switzerland) was used to measure the MIC, with absorption assessed at 560 nm.

Enzyme-linked immunosorbent assay (ELISA) detection of IL-8
-----------------------------------------------------------

Secreted IL-8 was measured using an ELISA kit (R&D Systems, USA). Briefly, AGS cells (2 × 10^5^/well) were seeded in 6-well plates. Suspensions of *H. pylori* at OD~600~ 1.0 were treated with various concentrations of CBD, amoxicillin, or clarithromycin for 24 h, and then applied to the AGS cells for 6 h. Supernatants were collected, and the levels of secreted IL-8 were measured as described by the manufacturer.

Animal experiment
-----------------

Male 4-week-old C57BL/6 mice (Orient Bio Co., Korea) were maintained on standard rodent chow with a 12 h light/dark cycle. All protocols involving animals were approved by the Animal Experimental Ethics Committee of Chungnam National University (Korea; approval No: CNU-00444). We conducted a preliminary trail with 3 doses of CBD (100, 500, and 1,000 mg/kg) to identify the optimum dose. Based on these experiments, we chose a dose of 100 mg/kg/day as a low concentration or 500 mg/kg/day as a high concentration, because these doses reduced *H.pylori*-induced gastritis-related parameters (data not shown).

The mice were allocated to 5 groups (n = 10/group) randomly as per the scheme shown in [Fig. 1A](#F1){ref-type="fig"}. Mice in the uninfected control group received PBS, while those in the infected groups were infected orally with *H. pylori* SS1 (1 × 10^9^ CFU/mL/mouse) 3 times at 2-day intervals. Two weeks after inoculation, mice in the infected control group received PBS for 7 days, mice in the triple therapy group were treated daily by gavage for 1 week with omeprazole (400 µmol/kg), amoxicillin (28.6 mg/kg), and clarithromycin (14.3 mg/kg) (OAC), and mice in the CBD-treated groups were orally gavaged each day with the indicated concentrations of CBD for 4 weeks. The animals had no access to food or water for 6 h before and after each inoculation. At 1 week after the last treatment, the mice were sacrificed.

![Animal experiment and 3D chromatogram. (A) Experimental protocol for development of *H. pylori*-infected murine model. Mice received intragastric inoculations of *H. pylori* SS1 (1 × 109 CFU/mouse; arrow heads) or vehicle (empty arrow head) 3 times at 2 day intervals and treatment with CBD (100 or 500 mg/kg) or OAC. (B) 3D chromatogram of CBD obtained using HPLC--PDA.\
3D, three-dimensional; CBD, Cheonwangbosim-dan; CFU, colony-forming unit; NC, normal control; OAC, omeprazole (400 μmol/kg), amoxicillin (28.6 mg/kg), and clarithromycin (14.3 mg/kg); HPLC--PDA, high-performance liquid chromatography photo-diode array; 5-HMF, 5-(hydroxymethyl)-2-furaldehyde.](jvs-21-e39-g001){#F1}

Histopathological examination
-----------------------------

Stomach tissues fixed with 10% neutral buffered formalin were washed, processed, and embedded in paraffin. Blocks were sectioned (4 μm) and stained with hematoxylin and eosin for examination by microscopy. The inflammation scores were graded as previously described \[[@B19]\].

Quantification of DNA from *H. pylori*
--------------------------------------

Gastric samples were subjected to extraction of genomic DNA using a QIAamp DNA Mini Kit (Qiagen, USA) as per the manufacturer\'s protocol. Quantification of *H. pylori* 16S ribosomal DNA (rDNA) was performed using TaqMan Master Mix (Life Technologies, USA) and an Applied Biosystems 7500 Real-Time PCR System (Life Technologies). The fold changes of target gene expression were calculated relative to that of the endogenous control (glyceraldehyde 3-phosphate dehydrogenase \[GAPDH\]).

Measurement of MDA
------------------

Frozen stomach tissues were homogenized with lysis buffer and centrifuged at 12,000 × g and 4°C for 10 min. Supernatants were collected and the level of MDA was quantified using an appropriate assay kit (Cell Biolabs, USA) according to the manufacturer\'s protocol.

Real-time quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------

Total RNA was isolated with the TRIZOL reagent (Thermo Scientific, USA) and complementary DNA was generated from 1 μg total RNA using a ReverTraAce qPCR RT kit (TOYOBO, Japan) according to the manufacturer\'s protocol. PCR was performed using SYBR Green PCR Master Mix and an Applied Biosystems 7500 Real-Time PCR System (Life Technologies). The fold change in the expression of the target gene relative to that of GAPDH was assessed using the 2^−ΔΔCt^ method.

Western blotting analysis
-------------------------

Proteins were resolved by 8--12% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P PVDF Membranes (Millipore, USA) by electroblotting. The membranes were blocked with 5% bovine serum albumin for 1 h and then incubated with anti-iNOS, anti-COX-2, anti-phospho p38 mitogen-activated protein kinase (MAPK), anti-p38 MAPK, anti-phospho-c-Jun N-terminal kinase (JNK), anti-JNK, anti-phospho-extracellular signal-regulated kinases 1/2 (ERK1/2), anti-ERK1/2 (all from Cell Signaling Technology and diluted 1:1,000), or anti-β-actin (Sigma, 1:1,500) antibodies overnight at 4°C. The membranes were washed, incubated with anti-mouse or -rabbit secondary antibodies for 2 h at room temperature, washed again, and visualized using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific).

Statistical analysis
--------------------

The results are expressed as the means ± standard deviation. One-way analysis of variance followed by Tukey\'s multiple comparison test were used to compare groups. The *p* \< 0.05 was considered as representing a significant difference.

RESULTS
=======

HPLC analysis of the CBD extract
--------------------------------

A 3-dimensional (3D) chromatogram of the CBD sample was obtained using an established HPLC--PDA method \[[@B18]\]. The 7 marker compounds, 5-HMF, coptisine chloride, berberine chloride, nodakenin, (*E*)-harpagoside, cinnamic acid, and *β*-asarone, were eluted within 40 min; their retention times were 7.81, 14.78, 16.36, 17.29, 22.30, 23.76, and 32.84 min, respectively. The 3D HPLC chromatogram of a representative CBD sample is shown in [Fig. 1B](#F1){ref-type="fig"}. The concentrations of 5-HMF, coptisine chloride, berberine chloride, nodakenin, (*E*)-harpagoside, cinnamic acid, and *β*-asarone in the CBD sample, as assessed using HPLC--PDA, were 0.25, 2.54, 12.74, 1.27, 0.26, 0.09, and 1.49 mg/freeze-dried g, respectively.

CBD has antimicrobial susceptibility against *H. pylori*
--------------------------------------------------------

The antimicrobial susceptibility of CBD against 4 strains of *H. pylori* was investigated using the disk agar diffusion method. The growth inhibition zones of amoxicillin and clarithromycin against the 4 tested strains were showed in [Table 2](#T2){ref-type="table"}. Interestingly, strain PED3582GA showed resistance against clarithromycin (inhibition zone, 0 mm at 2 μg/disk). CBD showed anti-*H. pylori* activity against all 4 strains, with growth inhibition zones in the range of 11--29 mm at 2,000 μg/disk. The MICs of CBD and the tested antibiotics against 4 *H. pylori* strains are presented in [Table 3](#T3){ref-type="table"}.

###### Inhibition zone diameters determined by the disk agar diffusion method
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  Extract/antibiotics     Diameter of growth inhibition zone (mm)             
  ----------------------- ----------------------------------------- ---- ---- ----
  CBD (2,000 µg)          11                                        22   29   15
  Amoxicillin (2 µg)      30                                        25   38   36
  Clarithromycin (2 µg)   46                                        56   0    4

CBD, Cheonwangbosim-dan.

###### MIC
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  Extract/antibiotics      MIC                        
  ------------------------ -------- -------- -------- --------
  CBD (µg/mL)              800      400      1,600    400
  Amoxicillin (µg/mL)      0.0313   0.1250   0.0625   0.0039
  Clarithromycin (µg/mL)   0.0039   0.0020   32       0.0020

MIC, minimum inhibitory concentration; CBD, Cheonwangbosim-dan.

Secretion of IL-8 by AGS cells is suppressed by CBD
---------------------------------------------------

As IL-8 is known to play a critical role in the immunopathology of *H. pylori*-associated gastroduodenal disease \[[@B20]\], we evaluated the effect of CBD on IL-8 secretion. *H. pylori* infection was associated with a significant increase in IL-8 concentration in the conditioned medium of AGS cells; however, this increase was suppressed in a dose-dependent manner by CBD, amoxicillin, or clarithromycin ([Fig. 2A](#F2){ref-type="fig"}).

![The effect of CBD on the secretion of IL-8 and the expression of COX-2 and iNOS in AGS cells infected with *H. pylori*. Suspensions of *H. pylori* at OD~600~ 1.0 were treated with CBD (400--1,600 μg/mL), Amo (0.02--0.08 μg/mL), or Cla (4--8 ng/mL) for 24 h and applied to AGS cells for 6 h. (A) IL-8 levels in AGS cells. (B) The protein levels of COX-2 and iNOS in AGS cells. β-actin was used as an endogenous control.\
All data are presented as the mean ± standard deviation.\
CBD, Cheonwangbosim-dan; IL, interleukin; COX-2, cyclooxygenase-2; iNOS, nitric oxide synthase; Amo, amoxicillin; Cla, clarithromycin; NC, normal control.\
^\*^*p* \< 0.01 vs. the control group; ^\*\*^*p* \< 0.01 vs. the *H. pylori* group.](jvs-21-e39-g002){#F2}

CBD decreases the expression of COX-2 and iNOS in AGS cells
-----------------------------------------------------------

As a previous study indicated that *H. pylori* infection up-regulates the levels of COX-2 and iNOS in host cells or tissues \[[@B21]\], we evaluated the levels of these proteins. As expected, infection of AGS cells with *H. pylori* increased the expression levels of COX-2 and iNOS. However, CBD, amoxicillin, or clarithromycin decreased these changes ([Fig. 2B](#F2){ref-type="fig"}).

CBD attenuates the histological changes induced by *H. pylori*
--------------------------------------------------------------

Next, we tested the therapeutic effect of CBD against *H. pylori* infection in an animal model. As shown in [Fig. 3A](#F3){ref-type="fig"}, inflammatory cells (e.g., macrophages, lymphocytes, and neutrophils) were infiltrated in gastric mucosa and submucosa of *H. pylori-*infected mice compared to uninfected controls, and treatment with OAC or CBD suppressed these changes. In addition, the inflammation scores were reduced in infected mice treated with OAC or CBD compared to infected mice that did not receive these treatments ([Fig. 3B](#F3){ref-type="fig"}).

![CBD attenuates the histological changes, bacterial colonization, and oxidative stress induced by *H. pylori*. (A) Formalin-fixed stomach sections were stained with hematoxylin and eosin and examined under a microscope (×40 and ×100). (B) Inflammation scores obtained from histological analysis. (C) The relative levels of *H. pylori* 16S ribosomal DNA were quantified.(D) MDA level of in gastric tissues of mice infected with *H. pylori*.\
All data are presented as the mean ± standard deviation.\
CBD, Cheonwangbosim-dan; IL, interleukin; MDA, malondialdehyde; ND; not detected; OAC, omeprazole, amoxicillin, and clarithromycin; NC, normal control.\
^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 vs. the control group; ^\*\*\*^*P* \< 0.05, ^\*\*\*\*^*P* \< 0.01 vs. the *H. pylori* group.](jvs-21-e39-g003){#F3}

CBD reduces colonization of *H. pylori* in mice
-----------------------------------------------

To investigate the colonization of *H. pylori* to the stomachs of mice, we quantified *H. pylori* 16s rDNA in stomach samples obtained from the various groups. Our results revealed that the normal control group had no detectable level of *H. pylori*, the infected group had a detectable level of *H. pylori* colonization, and this level was reduced in groups treated with OAC or CBD compared to the infected group ([Fig. 3C](#F3){ref-type="fig"}).

CBD reduces MDA level in mice
-----------------------------

The early stages of *H. pylori* infection are characterized by an increase in the MDA level, which is due to oxidative changes and contributes considerably to mucosal damage \[[@B22]\]. Here, we observed that infection of *H. pylori* increased the MDA level in mice, whereas treatment with OAC or CBD reduced this level ([Fig. 3D](#F3){ref-type="fig"}).

CBD suppresses cytokine expression in mice
------------------------------------------

To evaluate the effect of CBD on pro-inflammatory cytokine production, we measured the gastric levels of C-X-C motif chemokine ligand 1 (CXCL1), TNF-α, IL-1β, and IL-6. We found that *H. pylori* infection significantly increased the expression levels of CXCL1, TNF-α, IL-1β, and IL-6, but that these increases were significantly inhibited by treatment with OAC or CBD ([Fig. 4](#F4){ref-type="fig"}).

![CBD suppresses the mRNA expression levels of cytokines in gastric tissues of mice infected with *H. pylori*, as assessed by RT-qPCR. (A) The mRNA levels of CXCL1. (B) The mRNA levels of TNF-α. (C) The mRNA levels of IL-6. (D) The mRNA levels of IL-1β. All data are presented as the mean ± standard deviation.\
CBD, Cheonwangbosim-dan; OAC, omeprazole, amoxicillin, and clarithromycin; mRNA, messenger RNA; RT-qPCR, real-time quantitative polymerase chain reaction; IL, interleukin; CXCL1, C-X-C motif chemokine ligand 1; TNF-α, tumor necrosis factor alpha; NC, normal control.\
^\*^*P* \< 0.01 vs. the control group; ^\*\*^*P* \< 0.05, ^\*\*\*^*P* \< 0.01 vs. the *H. pylori* group.](jvs-21-e39-g004){#F4}

CBD decreases the expression levels of COX-2 and iNOS in mice
-------------------------------------------------------------

The trend in COX-2 and iNOS expression levels that we observed in our animal model resembled those that we recorded in AGS cells. Specifically, expression levels of COX-2 and iNOS in mice increased following *H. pylori* infection, but treatment with OAC or CBD reduced this effect ([Fig. 5A and B](#F5){ref-type="fig"}).

![CBD suppresses the protein expression levels of COX-2, iNOS and the phosphorylation levels of MAPK family members in gastric tissues of mice infected with *H. pylori*. (A) Expression of COX-2 in stomach tissues. (B) Expression of iNOS in gastric tissues. (C) Expression levels of phosphorylated and total p38 MAPK, JNK, and ERK1/2 in stomach tissues. The protein levels were analyzed by immunoblotting. β-actin was used as an endogenous control.\
All data are presented as the mean ± standard deviation.\
CBD, Cheonwangbosim-dan; COX-2, cyclooxygenase-2; iNOS, nitric oxide synthase; NC, normal control; MARK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; ERK1/2, extracellular signal-regulated kinases 1/2; OAC, omeprazole, amoxicillin, and clarithromycin.\
^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 vs. the control group; ^\*\*\*^*P* \< 0.05, ^\*\*\*\*^*P* \< 0.01 vs. the *H. pylori* group.](jvs-21-e39-g005){#F5}

CBD reduces the activation of MAPK family members in mice
---------------------------------------------------------

In an effort to determine the mechanism underlying the antimicrobial and anti-inflammatory effects of CBD, we analyzed the protein levels of various MAPK family members. We found that the phosphorylation levels of p38 MAPK, ERK1/2, and JNK were elevated in *H. pylori*-infected mice compared to normal control mice, but treatment OAC or CBD significantly suppressed these activating phosphorylations ([Fig. 5C](#F5){ref-type="fig"}).

DISCUSSION
==========

The possibility of zoonotic transmission of *H. pylori* has been suggested. A recent studies reported high presence of *H. pylori* strains in stomach of domestic animals, milk and meat similar to vac A genotypes in human being, suggesting food with animal origin may be its reservoirs \[[@B23][@B24]\]. There is currently an unmet need for potent therapeutic agents against *H. pylori* that can avoid the increasing issues of antimicrobial resistance while ideally offering lower cost and fewer side effects and contraindications \[[@B25]\]. Many natural products such as *Qualea parviflora* and *Byrsonima intermedia* have been reported their antimicrobial activity against *H. pylori*, and various plants and substances derived from alternative sources have been treated for gastrointestinal diseases \[[@B26]\].

In our HPLC--PDA data 7 major components of CBD are 5-HMF, coptisine chloride, berberine chloride, b-asarpme, cinnamic acid, (*E*)-harpagoside and nodakenin. In the previous studies, 5-HMF showed protective effect against oxidative injury and mitigated inflammation via MAPK pathway \[[@B27][@B28]\]. Especially, coptisine inhibited *H. pylori* by inhibiting urease activity \[[@B29]\]. Berberine also inhibited enterobacterial growth in colitis mouse model \[[@B30]\]. Each component contributed to anti-*H. pylori* effect, but further study will be needed to clarify which components is responsible for the anti-inflammatory activity and anti-microbial activity of CBD against H. pylori-induced gastritis.

In the present study, we evaluated the efficacy of CBD against 4 different *H. pylori* strains (26695, SS1, PED3582GA, and PED503G); its MIC ranged from 400 to 1,600 μg/mL and the growth inhibition zones obtained in our disk assay ranged from 11 to 29 mm. Amoxicillin standard by European Committee on Antimicrobial Susceptibility Testing (EUCAST) to MIC breakpoints are susceptible ≤ 0.125 mg/L and resistant \> 0.125 mg/L. Clarithromycin standard by EUCAST to MIC breakpoints are susceptible ≤ 0.25 mg/L and resistant \> 0.5 mg/L \[[@B31]\]. CLSI provides a guideline only for an agar dilution method. Disk diffusion criteria for antimicrobial susceptibility testing of *H. pylori* have not yet been defined. It is not standardized and can be only susceptible or resistant \[[@B32]\]. PED3582GA exhibited no growth inhibition zone for clarithromycin, but was greatly inhibited by CBD comparing to other strains. This suggests that CBD might has better antimicrobial susceptibility for this strain.

IL-8 plays a critical role in the response of gastric epithelial cells to *H. pylori* infection, and its level is remarkably elevated in the gastric mucosal tissues of *H. pylori*-positive patients \[[@B33]\]. ROS mediate the expression of IL-8 that can induce proinflammatory cytokines, such as IL-1β, IL-6, IL-12, interferon-γ, and TNF-α, which regulate the inflammatory response \[[@B34]\]. In this study, CBD significantly reduced the *in vitro* secretion of IL-8 by AGS cells. *In vivo*, we found that OAC or CBD treatment decreased the *H. pylori*-induced up-regulations of pro-inflammatory cytokines (CXCL1, IL-1β, IL-6, and TNF-α) and inflammatory cell infiltration into stomach tissues.

The chemotactic ability of IL-8 can attract cells to sites of infection and inflammation \[[@B35]\]. The inflammatory cells recruited to the stomach during *H. pylori* infection can induce ROS; this triggers lipid peroxidation, which is associated with different gastroduodenal diseases \[[@B36]\]. MDA, which is a lipid peroxidation product that can serve as a biomarker for oxidative stress, is reportedly elevated in the gastric mucosa of patients infected with *H. pylori* \[[@B22]\]. Furthermore, the MDA level of gastric juice was proposed to be related with the severity of gastric disease \[[@B37]\]. Here, we show that CBD treatment dose-dependently reduced the inflammation score and *H. pylori* colonization in parallel with its ability to reduce the MDA level in mice. These results indicate that CBD effectively ameliorates oxidative stress, thereby decreasing the risk for gastric injury.

To further validate the anti-inflammatory effect of CBD, we evaluated COX-2 and iNOS, which are important regulators of mucosal inflammation in *H. pylori-*induced gastric injury \[[@B38]\]. In *H. pylori*-infected AGS cells and the stomach tissues of *H. pylori*-infected mice, the protein expression levels of COX-2 and iNOS were up-regulated compared to the control levels, and these changes were suppressed by CBD or antibiotics. As the severity of gastric injury is associated with the protein expression levels of COX-2 and iNOS in stomach tissues, the inhibition of these inflammatory enzymes may be a valuable strategy for treating the gastric diseases induced by *H. pylori* \[[@B39]\].

The MAPK family includes 3 major subclasses: p38, ERK1/2, and JNK \[[@B12]\]. The MAPKs are believed to mediate *H. pylori*-induced IL-8 expression and regulate transcription factors (e.g., NF-κB and AP-1) that modulate cytokine gene expression \[[@B40]\]. Here, we found that *H. pylori* infection activated MAPK signaling, as represented by increased phosphorylation of p38, ERK1/2, and JNK, and that these *H. pylori*-induced activations were inhibited by CBD or OAC. Since the MAPK family members regulate inflammatory and immune responses \[[@B28]\], their inhibition may contribute to reducing the proinflammatory milieu to suppress inflammatory events. We herein demonstrate that CBD suppresses the *H. pylori*-induced production of pro-inflammatory mediators, as well as its ability to trigger oxidative stress and MAPK activation. Taken together, our results reveal that CBD could prove useful for treating *H. pylori*-induced gastric injury.

**Funding:** The present research was supported by a grant from the Korea Institute of Oriental Medicine (KIOM; Evaluation of Herb-Drug Interactions, K16252).

**Conflict of Interest:** The authors have no conflicts of interest to declare.

**Author Contributions:** **Conceptualization:** Kwon HJ.**Data curation:** Park HS, Jeong HY, Kim YS.**Formal analysis:** Park HS.**Methodology:** Jeong HY, Kim YS.**Project administration:** Kwon HJ.**Resources:** Seo CS, Ha H.**Writing - original draft:** Seo CS, Ha H, Park HS.**Writing - review & editing:** Kwon HJ.
